Stallergenes is focused on the development, manufacture, and distribution of immunotherapeutic treatments for food-related and environmental allergies. The company has brought together experts from the fields of biology, botany, and the health community to collaborate on finding ways to deliver relief to people who suffer with problems ranging from asthma to seasonal allergies. These immunotherapy treatments involve conditioning the patient with drugs that introduce pure extracts of the allergen to initiate the body's own natural defenses against it. Wendel Investissement owns about 49% of the company. Stallergenes has research laboratories in Africa, the Americas, Asia, Australia, Europe, and the Middle East.

Third Wave Technologies is riding the biotech breakers. Using its Invader technology, Third Wave develops molecular diagnostic tests that detect genetic variations associated with a variety of conditions, including cystic fibrosis, cardiovascular risk factors, and infectious disease. Some tests can determine a patient's likely response to certain drugs, making it possible for doctors to avoid prescribing a drug that might cause dangerous side effects. Third Wave company has a strong presence in Japan, where it has a collaboration agreement with genetic researchers at the University of Tokyo. Third Wave Technologies was acquired by Hologic in 2008 for $580 million.

Cambridge Laboratories Limited company was founded in 1987 and is now owned by its board of directors. Cambridge Laboratories develops and distributes pharmaceuticals to treat the central nervous system, cancer, vitamin deficiency, and other niches. Its product line includes ImmuCyst (for treatment of superficial bladder cancer), Nabilone (chemotherapy-related nausea and vomiting), and Gelclair (oral ulcers and inflammation). Cambridge Labs has distribution alliances to market its products in over 40 countries.

PLIVA wants you to remember its scientific research and business acumen, and less the names of its products. PLIVA company develops and produces generic pharmaceuticals, particularly in the anti-inflammatory and anti-infective areas. PLIVA also produces the active pharmaceutical ingredients used by other drug makers. Its products include both prescription and over-the-counter drugs, pills, creams, and injectables. PLIVA was founded in 1921 and operates in more than 30 countries. The company is a subsidiary of global generics firm Teva Pharmaceutical.

Alexion Pharmaceuticals was founded in 1992 and is headquartered in Cheshire, Connecticut. Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and delivers drug therapies for patients with various medical conditions. It primarily engages in the discovery, development, and commercialization of biologic therapeutic products for the treatment of various disease states, including hematologic and neurologic diseases, transplant rejection, cancer, and autoimmune disorders. The company primarily markets Soliris (eculizumab) in the United States and Europe for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a blood disorder. It is also evaluating other indications for Soliris, as well as other formulations of eculizumab for additional clinical indications. In addition, the company is developing Anti-CD200 antibody for the treatment of B-Cell Chronic Lymphocytic Leukemia, a cancer that results from expansion of B-lymphocytes and other cancers.Alexion Pharmaceuticals drug programs include Eculizumab (intravenous), a phase II product candidate for atypical HUS, presensitized renal transplant, myasthenia gravis, multifocal motor neuropathy, dense deposit disease, catastrophic antiphospholipid syndrome, and cold agglutinin disease; CD200 Mab, which is in phase I/II clinical trial for the treatment of chronic lymphocytic leukemia and in preclinical stage for the treatment of multiple myeloma; and Eculizumab (new formulation) that is under phase I/II clinical trial for the treatment of asthma. Its customers include specialty distributors and specialty pharmacies who supply physician office clinics, hospital outpatient clinics, infusion clinics, or home health care providers; government agencies; and hospitals, hospital buying groups, pharmacies, and other health care providers and distributors.

AstraZeneca was founded in 1992 and is headquartered in London, the United Kingdom. AstraZeneca plc (LSE: AZN) operates independently of Imperial Chemical Industries plc as of June 1, 1993. AstraZeneca plc discovers, develops, manufactures, and markets prescription pharmaceuticals and biological products in the areas of cardiovascular, gastrointestinal, neuroscience, oncology, respiratory and inflammation, and infection worldwide. Its primary products include Arimidex for hormonal breast cancer; Crestor that provides treatment for managing cholesterol levels; Nexium for acid-related diseases; Seroquel, an atypical anti-psychotic therapy for treating schizophrenia and bipolar mania; and Symbicort for the treatment of asthma in patients.AstraZeneca company also engages in the research, development, manufacture, and marketing of medical devices and implants for use in urology, surgery, and odontology. In addition, it develops and manages hospital-based outpatient cancer centers in the United States; and produces individually adapted abutments for dental implants using a patented CAD/CAM method. The company markets its products to primary care and specialist physicians, as well as to other healthcare professionals, governments, and healthcare buying groups through sales and marketing network, local marketing companies, distributors, and local representative offices. It has collaboration agreements with Bristol-Myers Squibb Company; POZEN Inc.; Abbott laboratories; Palatin Technologies, Inc; BioDuro Inc.; Jubilant Organosys Ltd.; Merck & Co. Inc.; Cancer Research Technology Limited; Institute of Cancer Research; Alcon Inc.; Mental Health Research Institute; Targacept, Inc.; and Dako Denmark A/S. AstraZeneca also has a drug discovery and development agreement with PsychoGenics Inc. to identify compounds that are useful for the treatment of certain central nervous system disorders.

The Whitehead Institute for Biomedical Research blazes new trails in bioscience. The organization, funded by both the public and private sectors, investigates such diseases as Parkinson's and cancer and dives into the depths of biology, genomics, and genetics to gain new understanding about disease and health. The Whitehead Institute contributed to the international effort to map the human genome, and is actively researching stem cells. Other achievements include discovering a system for multiplying adult stem cells and creating the first genetically defined human cancer cell. The institute was founded in 1982 by philanthropist Edwin "Jack" Whitehead and draws researchers from MIT.

Hemispherx Biopharma, based in Philadelphia, is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of viral and immune-based disorders. Hemispherx’s flagship products include Alferon N Injection® and the experimental immunotherapeutics/antivirals Ampligen® and Oragens®.Alferon N Injection® is the company's registered trademark for its injectable formulation of Natural Alpha Interferon, and is approved by the FDA for a category of STD infection. Alferon N Injection® (interferon alfa-n3 human leukocyte derived) is a highly purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. Alferon LDO® (Low Dose Oral) is a new experimental drug delivery platform for the Company’s highly purified, natural source alpha interferon.

Surface Logix creates new drugs by tweaking the pharmacokinetic and pharmacodynamic properties of existing drugs and new compounds. Its Pharmacomer Technology improves a drug's solubility and permeability in the body and reduce side effects. It has a pipeline of pre-clinical and clinical candidates in development for treatment of metabolic diseases and hypertension. Its drug candidate SLx-4090 is in clinical trials to test its ability to lower blood lipid levels, reduce triglyceride uptake, and block absorption of other fats. Its SLx-2101 candidate is being investigated for treatment of hypertension and Raynaud's Syndrome.

Allos Therapeutics, Inc. was founded in 1992 and is headquartered in Westminster, Colorado. Allos Therapeutics, Inc. is a biopharmaceutical company that is focused on developing and commercializing small molecule drugs for the treatment of cancer. The Company’s lead product candidate, pralatrexate (PDX) an antifolate, is in Phase II trial in patients with relapsed or refractory peripheral T-cell lymphoma. The Company is also investigating PDX in patients with non-small cell lung cancer and a range of other lymphoma sub-types. The Company’s other product candidate is RH1, a targeted chemotherapeutic agent, which is in a Phase I trial in patients with advanced solid tumors or non-Hodgkin's Lymphoma. In February 2009, the Company announced the final results from PROPEL, its pivotal Phase II trial of pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This trial was conducted under an agreement reached with the United States Food and Drug Administration (FDA) under its special protocol assessment (SPA) process.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.